Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C

Vijayan Balan, David R. Nelson, Mark S. Sulkowski, Gregory T. Everson, Louis Lambiase, Rusell H. Wiesner, Rolland C. Dickson, Andy Garcia, Paul A. Moore, Ren Yu, G. Mani Subramanian

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500-900 μg) alb-IFN cohort, who received two injections on day O and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients (P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 (P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.

Original languageEnglish (US)
Pages (from-to)901-908
Number of pages8
JournalAntiviral Therapy
Volume11
Issue number7
StatePublished - Nov 17 2006
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Interferons
Gene Expression
Antiviral Agents
Albumins
Recombinant Proteins
Hepacivirus
Genes
Half-Life
Real-Time Polymerase Chain Reaction
albumin interferon
RNA
Peptides
Injections
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Balan, V., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Lambiase, L., Wiesner, R. H., ... Subramanian, G. M. (2006). Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C. Antiviral Therapy, 11(7), 901-908.

Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C. / Balan, Vijayan; Nelson, David R.; Sulkowski, Mark S.; Everson, Gregory T.; Lambiase, Louis; Wiesner, Rusell H.; Dickson, Rolland C.; Garcia, Andy; Moore, Paul A.; Yu, Ren; Subramanian, G. Mani.

In: Antiviral Therapy, Vol. 11, No. 7, 17.11.2006, p. 901-908.

Research output: Contribution to journalArticle

Balan, V, Nelson, DR, Sulkowski, MS, Everson, GT, Lambiase, L, Wiesner, RH, Dickson, RC, Garcia, A, Moore, PA, Yu, R & Subramanian, GM 2006, 'Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C', Antiviral Therapy, vol. 11, no. 7, pp. 901-908.
Balan, Vijayan ; Nelson, David R. ; Sulkowski, Mark S. ; Everson, Gregory T. ; Lambiase, Louis ; Wiesner, Rusell H. ; Dickson, Rolland C. ; Garcia, Andy ; Moore, Paul A. ; Yu, Ren ; Subramanian, G. Mani. / Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C. In: Antiviral Therapy. 2006 ; Vol. 11, No. 7. pp. 901-908.
@article{199fbd1e556c47daa1d8801b2a9364d1,
title = "Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C",
abstract = "Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500-900 μg) alb-IFN cohort, who received two injections on day O and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients (P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 (P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.",
author = "Vijayan Balan and Nelson, {David R.} and Sulkowski, {Mark S.} and Everson, {Gregory T.} and Louis Lambiase and Wiesner, {Rusell H.} and Dickson, {Rolland C.} and Andy Garcia and Moore, {Paul A.} and Ren Yu and Subramanian, {G. Mani}",
year = "2006",
month = "11",
day = "17",
language = "English (US)",
volume = "11",
pages = "901--908",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "7",

}

TY - JOUR

T1 - Modulation of interferon-specific gene expression by albumin-interferon- α in interferon-α-experienced patients with chronic hepatitis C

AU - Balan, Vijayan

AU - Nelson, David R.

AU - Sulkowski, Mark S.

AU - Everson, Gregory T.

AU - Lambiase, Louis

AU - Wiesner, Rusell H.

AU - Dickson, Rolland C.

AU - Garcia, Andy

AU - Moore, Paul A.

AU - Yu, Ren

AU - Subramanian, G. Mani

PY - 2006/11/17

Y1 - 2006/11/17

N2 - Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500-900 μg) alb-IFN cohort, who received two injections on day O and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients (P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 (P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.

AB - Albumin-interferon-α (alb-IFN) is a novel recombinant protein derived from IFN-α2b genetically fused to human albumin. The resulting single polypeptide combines in one molecule the antiviral properties of IFN-α with the long serum half-life of albumin. IFN-mediated biological responses stem from the engagement of IFN-α with its target receptor and subsequent modulation of IFN-specific gene (ISG) expression. To evaluate the pharmacodynamics of alb-IFN during the Phase I/II study conducted in patients with chronic hepatitis C (CHC) who had previously failed IFN-α-containing regimens, ISG induction was evaluated in peripheral blood and compared with antiviral response. Whole blood was obtained at day 0, day 7 and day 28 from 21 patients enrolled in the higher dose (500-900 μg) alb-IFN cohort, who received two injections on day O and day 14. Taqman real-time PCR was used to assess candidate ISG expression. There was sustained induction on day 7 and day 28 of the ISG's OAS1, IRF-7, IFI44 and IFI27. Although all patients showed a molecular response to alb-IFN, individual variability in pretreatment gene expression levels and fold of modulation during treatment was observed. At day 28, induction of OAS1, IFI44 and IRF7 showed pairwise correlation in individual patients (P<0.05). Moreover, the induction of expression at day 28, and pretreatment levels of OAS1 and IFI44 correlated with hepatitis C virus RNA reduction at day 28 (P<0.05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-α.

UR - http://www.scopus.com/inward/record.url?scp=33750937197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750937197&partnerID=8YFLogxK

M3 - Article

C2 - 17302252

AN - SCOPUS:33750937197

VL - 11

SP - 901

EP - 908

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 7

ER -